James R. Berenson, MD, Inc.

Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.

Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of clinical trails for cnacer, will present final results from a multicenter clinical trial at the American Society of Hematology Annual Meeting in San Diego, CA on December 10-13, 2011.

The results of this landmark study should be welcomed news to cancer patients across the world suffering from the debilitating effects of painful vertebral compression fractures,” said Dr. James Berenson, the study’s first author and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research in Los Angeles, CA. “It is documented [...]